References
- Lokich J, Bothe A, Fine N, Perri I. Phase I study of protracted venous infusion of 5-fluorouracil. Cancer 1981; 48: 2565–2568
- Lokich J, Fine N, Perri J, Both A. Protracted ambulatory venous infusion of 5-fluorouracil. Am J Clin Oncol 1983; 6: 103–107
- Caballero G A, Ausman R K, Quebbeman E J. Long term, ambulatory, continuous intravenous infusion of 5-fluorouracil for treatment of advanced adenocarcinomas. Cancer Treat Rep 1985; 69: 13–15
- Quebbeman E, Ausman R, Hansen R. Long term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. J Surg Oncol 1985; 30: 60–65
- Wade J L, Herbst S, Greenburg A. Prolonged venous infusion (PVI) of 5-fluorouracil (5-FU) for metastatic colon cancer. Proc ASCO 1986; 5: 88, C-341
- Lokich J, Ahlgren J, Gullo J. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425–432
- Hansen R, Quebbeman E, Ausman R. Continuous systemic 5-fluorouracil (5-FU) infusion in advanced colorectal cancer. Results in 91 patients. J Surg Oncol 1989; 40: 177–181
- Benedetto P, Bogos M, Morillo G. Chronic continuous infusion of 5-fluorouracil (CCI-FU) in previously untreated patients with measurable metastatic colorectal cancer. Proc ASCO 1986; 5: 92, 358
- Faintuch J S, Shepard K V, Gaynor E. Continuous infusion 5FU—a dose escalating schedule. Proc ASCO 1986; 5: 93, 363
- Reiter B, Schreibman S, Adler S. Treatment of colorectal cancer with 5FU by infusion in a community oncology practice. Proc ASCO 1987; 6: 74, 288
- Belt R J, Davidner M L, Myron M C. Continuous low-dose 5-fluorouracil (5-FU) for adenocarcinoma: Confirmation of activity. Proc ASCO 1985; 4: 90, C-349
- Leichman L, Leichman C G, Kinzie J. Long-term low dose 5-fluorouracil (5FU) in advanced measurable colon cancer: No correlation between toxicity and efficacy. Proc ASCO 1985; 4: 86, C-333
- Hansen R, Quebbeman E, Ritch P. Continuous 5-fluo rouracil (5-FU) infusion in carcinoma of the pancreas. Am J Med Sci 1988; 295: 9–93
- Moynihan T, Hansen R, Anderson T. Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 1988; 11(4)461–464
- Hansen R, Quebbeman Ritch E. P. Continuous 5-fluorouracil (5-FU) infusion in refractory carcinoma of the breast. Breast Cancer Treat Res 1987; 10: 145–149
- Cantrell J, Hart R, Taylor R. Phase II trial of continuous infusion (CI) 5FU and weekly low dose cisplatin (DDP) in colorectal carcinoma. Proc ASCO 1986; 5: 84, 326
- Alhgren J, Gray R, Rothschild N. Phase II study of continuous infusion 5-fluorouracil (CIS-FU) plus weekly cisplatin (DDP) as second line therapy for advanced measurable colorectal adenocarcinoma. Proc ASCO 1987; 633(323)
- Grem J L, Hoth D F, Hamilton J M. Overview of current status and future direction of clinical trials with 5-fluorouracil in combination with folinic acid. Cancer Treat Rep 1987; 71: 1249–1264
- Einhom L H. Editorial: Improvements in fluorouracil chemotherapy. J Clin Oncol 1989; 7: 1377–1379
- Hines J D, Adelstein D J, Bast J. High-dose oral (PO) leu-covorin (CF) and intravenous 5-fluorouracil (5FU) in advanced metastatic colorectal carcinoma: Results of a pilot-phase I study. Roc ASCO 1988; 7: 110, 424
- Straw J A, Szapary D, Wynn W T. Pharmacokinetics of the dias-tereoisomers of leucovorin after intravenous and oral administration to normal subject. Cancer Res 1984; 44: 3114–3119
- Schneiderman M A. Mouse to man: Statistical problems in bnnging a drug to clinical trial. Proc Fifth Berkeley Symp Math Statis Prob, Univ. of California, Vol. 4. University of California Press, Berkeley 1967; 855–866
- Anderson N, Lokich J, Bern M. A phase I clinical trial of combined fluoropyrimidines with leucovorin in a 14-day infusion. A demonstration of biochemical modulation. Cancer 1989; 63: 233–237